As a board member at Theraclion and strategic advisor at other companies, Ari Kellen provides input on each firm's portfolio development.
Theraclion’s trademark product, Echo Pulse, aims to shrink thyroid nodules and breast fibroadenomas. Using novel technologies to address overlooked healthcare needs, Theraclion raises funds to support efforts in emerging uses of high-frequency ultrasound (HIFU). Theraclion is currently evaluating the efficacy and safety of HIFU as a non-invasive approach to treat varicose veins, a painful and disfiguring condition. Alternatives to HIFU include surgery and injections. The physician directs the thermal energy with a high-intensity ultrasound (HIFU) probe, and the HIFU passes through the skin, targeting the affected veins to shrink and seal them. Theraclion has been testing this new technology in Europe and in the USA with a small number of experienced physicians prior to enrolling more patients in larger clinical trials to prove safety and efficacy of the newer technology.
